Showing results (451-460 of 525) with videos related to

Sort By:
Pageof 53
Diabetes Care|August 16, 2022
Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium-Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY AnalysisPeter Rossing, Stefan D Anker, Gerasimos Filippatos, et al.
Hypertension (Dallas, Tex. : 1979)|February 5, 2019
Urine Haptoglobin and Haptoglobin-Related Protein Predict Response to Spironolactone in Patients With Resistant HypertensionMarta Martin-Lorenzo, Paula J Martinez, Montserrat Baldan-Martin, et al.
International Journal of Molecular Sciences|January 21, 2023
Partial Genetic Deletion of Klotho Aggravates Cardiac Calcium Mishandling in Acute Kidney InjuryLaura González-Lafuente, José Alberto Navarro-García, Ángela Valero-Almazán, et al.
ESC Heart Failure|September 3, 2024
Finerenone and left ventricular hypertrophy in chronic kidney disease and type 2 diabetesGerasimos Filippatos, Stefan D Anker, George L Bakris, et al.
Cardiovascular Diabetology|January 17, 2016
Urinary alpha-1 antitrypsin and CD59 glycoprotein predict albuminuria development in hypertensive patients under chronic renin-angiotensin system suppressionLaura Gonzalez-Calero, Marta Martin-Lorenzo, Fernando de la Cuesta, et al.
Clinical Kidney Journal|April 23, 2024
Validation of the Klinrisk chronic kidney disease progression model in the FIDELITY populationNavdeep Tangri, Thomas Ferguson, Silvia J Leon, et al.
Diabetes, Obesity & Metabolism|April 24, 2026
Outcomes With Finerenone by Baseline Treatment Goals in Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY AnalysisJoão Sérgio Neves, Ana Rita Leite, Francisco Vasques-Nóvoa, et al.
Kidney International Reports|January 10, 2022
Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor TherapyPeter Rossing, Gerasimos Filippatos, Rajiv Agarwal, et al.
Diabetes, Obesity & Metabolism|February 1, 2023
Effects of finerenone in people with chronic kidney disease and type 2 diabetes are independent of HbA1c at baseline, HbA1c variability, diabetes duration and insulin use at baselineJanet B McGill, Rajiv Agarwal, Stefan D Anker, et al.
Hypertension (Dallas, Tex. : 1979)|October 26, 2018
Prognostic Value of Masked Uncontrolled HypertensionSante D Pierdomenico, Anna M Pierdomenico, Francesca Coccina, et al.
Pageof 53